Lurasidone for schizophrenia: what's different?

Expert Review of Neurotherapeutics
Joshua T Kantrowitz, Leslie Citrome


Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia. Several Phase II and III studies have established that lurasidone is more efficacious than placebo. There are no available adequately powered head-to-head comparisons of efficacy of lurasidone with other antipsychotics. However, in contrast to some other antipsychotics, lurasidone is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the ECG QT interval. As per the product label, the recommended starting dose is 40 mg/day and the maximum recommended dose is 80 mg/day. Higher doses do not appear to be more efficacious, and may be associated with increases in adverse effects, such as somnolence and akathisia; however, this tolerability issue was not observed in one recently conducted 6-week study when lurasidone was administered at a dose of 160 mg/day. It is recommended that lurasidone be administered once daily with at least 350 calories of food. Additional studies are desirable to directly compare and contrast lurasidone with other antipsychotic agents.


Jul 15, 2015·Chemical Society Reviews·Tegan P Stockdale, Craig M Williams
Oct 1, 2013·European Journal of Pharmacology·Todd M Hillhouse, Adam J Prus
May 2, 2014·Expert Review of Neurotherapeutics·Cecilio AlamoPilar García-García
Dec 10, 2019·Postgraduate Medicine·Amir M MeftahJoshua T Kantrowitz


May 29, 1998·Circulation·P W WilsonW B Kannel
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jun 11, 2003·Archives of General Psychiatry·John M DavisIra D Glick
Oct 12, 2004·CNS Spectrums·Darius K Shayegan, Stephen M Stahl
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Mar 6, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Marta Di FortiRobin M Murray
Jan 4, 2008·The American Journal of Psychiatry·Keith H NuechterleinStephen R Marder
Apr 17, 2008·The American Journal of Psychiatry·Kristen A WoodberryLarry J Seidman
Nov 6, 2008·Expert Opinion on Drug Safety·Joshua T Kantrowitz, Leslie Citrome
Nov 26, 2008·The Journal of Clinical Psychiatry·Kuan GandelmanSheldon H Preskorn
Mar 28, 2009·Schizophrenia Bulletin·Oliver D Howes, Shitij Kapur
Apr 25, 2009·The Journal of Clinical Psychiatry·John M KaneSheila Assunção-Talbott
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Leslie Citrome
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Sep 29, 2009·Expert Opinion on Investigational Drugs·Jonathan M MeyerEdward Schweizer
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
May 14, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stephen M Stahl
Oct 1, 2010·Clinical Schizophrenia & Related Psychoses·Joshua T Kantrowitz, Daniel C Javitt
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Leslie Citrome
Apr 12, 2011·Expert Opinion on Drug Metabolism & Toxicology·Silvio Caccia
May 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·Masakuni HoriguchiHerbert Y Meltzer
May 13, 2011·Schizophrenia Bulletin·Jan Volavka, Leslie Citrome
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Jul 15, 2011·Therapeutics and Clinical Risk Management·Ludovic SamalinPierre-Michel Llorca
Aug 16, 2011·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·David R P Guay
Nov 1, 2011·Expert Opinion on Pharmacotherapy·Leslie Citrome
Dec 8, 2011·Drugs of Today·R T Owen

Related Concepts

Antipsychotic Effect
Phase 3 Clinical Trials
Other antipsychotics in ATC
Adverse Effects
Evaluation Studies, FDA Phase II as Topic
Antipsychotic Agents

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.